As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.

MedAdNews spoke to Bill Dreitlein, Senior Director, Pipeline & Drug Surveillance at OptumRx, about the state of the industry’s prescription drug pipeline and what enticing prospects will soon emerge.

Pharma companies from across the globe provide updates on their pipelines and business.

BioNTech will acquire Neon Therapeutics Inc. in an all-stock transaction valued at approximately $67 million.

Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates (ADCs) during a partnership that spanned seven years.

AstraZeneca topped the first annual Pharmaceutical Invention Index, released by IDEA Pharma.

Halozyme Therapeutics is restructuring after halting development of a metastatic pancreatic cancer drug that failed to demonstrate an improvement in overall survival in a Phase III trial.

Thousand Oaks, California-based Amgen significantly expanded the company’s presence in China by taking a 20.5 percent stake in BeiGene Co.

UCB will acquire U.S.-based Ra Pharmaceuticals in a $2.1 billion deal that will enable the Belgian drugmaker to offer new treatment options for several rare diseases in neurology and immunology.

German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.